FDA/CDC

CDC: Beware Brazil yellow fever outbreak


 

The Centers for Disease Control and Prevention recommends that travelers who haven’t been vaccinated against yellow fever should avoid travel to Brazil, according to a media teleconference by CDC officials.

“The most important new recommendation ... is that travelers should not go to these yellow fever hot spots in Brazil, unless they are vaccinated,” stated Martin Cetron, MD, director of the Division of Global Migration and Quarantine at the CDC. “Health officials in Brazil recently confirmed more than 920 cases of yellow fever, including more than 300 deaths, during this outbreak” he added.

Mosquito ©DamrongpanThongwat/thinkstock
Yellow fever is a fairly common infection in locations such as South America, and is spread by the bite of an infected mosquito, according to Dr. Cetron. He pointed out that Brazil’s yellow fever outbreak has been spreading into areas popular with tourists, including urban centers such as Rio De Janeiro.

Since the beginning of 2018, 10 travel-related cases of yellow fever have been reported among international travelers returning from Brazil. Four of these travelers died. All 10 travelers had not received the yellow fever vaccine. Of these 10 travelers, 8 acquired the disease on Ilha Grande, an island off the coast of Rio De Janeiro that is popular among tourists.

Pages

Recommended Reading

Dentist-prescribed antibiotics implicated in community-acquired C. diff
MDedge Internal Medicine
G. lamblia assemblage B more common in HIV-positive people
MDedge Internal Medicine
Post-Ebola syndrome includes neurologic sequelae
MDedge Internal Medicine
Steroids underused in bacterial meningitis despite low risk
MDedge Internal Medicine
Simple rule boosted yield of molecular tests for enteric pathogens
MDedge Internal Medicine
IGRA preferred test for latent TB diagnosis
MDedge Internal Medicine
Chikungunya virus goes undetected despite chronic arthritis in 25% of patients after 20 months
MDedge Internal Medicine
Recurrent serious infection risk captured in real world RA study
MDedge Internal Medicine
Mogamulizumab active in HTLV-1–associated myelopathy
MDedge Internal Medicine
Increasing sepsis survivorship creates new challenges
MDedge Internal Medicine